Trials
3 active
5 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Lennox Gastaut Syndrome, Dravet Syndrome
- Main trialPhase 3
- “This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).”In the company’s words, NCT05066217 on ClinicalTrials.gov
- Other names
- EPX-100 · clemizole · Clemizole hydrochloride
Other drugs for Lennox Gastaut Syndrome
- CarisbamateSK Life Science, Inc. · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- BMB-101Bright Minds Biosciences · Phase 2
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up2
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
- Apr 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Nov 2026 | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | |
| Phase 3Recruiting | Apr 2027 | A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | |
| Phase 1Recruiting | 30 Dec 2026 | A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants | |
| Phase 1Completed | 27 Nov 2019 | Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects. | |
| Phase 1Completed | 3 Apr 2025 | Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026